TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents
Phase Ib study of the safety and efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia: Big Ten Cancer Research Consortium BTCRC-AML17-113
Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092
Phase I trial of azacitidine plus nivolumab following reduced-intensity allogeneic PBSC transplantation for patients with AML and high-risk myelodysplasia. Big Ten Cancer Research Consortium BTCRC-AML18-342